The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York RFK Jr. & claimed regenerative peptides like BPC 157 The Niche FDA Moves to Reevaluate Several Peptides American Med Spa Association FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law